Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Aug 15, 2022 6:08pm
146 Views
Post# 34897819

RE:total liabilities dropped by $8M in H1

RE:total liabilities dropped by $8M in H1

Have to chuckle about Eugene's comments on Eiasi/Biogens new drug that read out's could be a catalyst for the the Alzheimers field. Heard that a couple of years ago about Biogen Aducamab was actually approved earlier by FDA what happened Promis stock went down. Eugene and Elliott must be getting tired of repeating the same old stuff. What's this discovery lab mentioned is it a new lab that they talked about in the Prospectus last August? If it is had to that keep that quiet so the stock would stay depressed.The ALS comments M101 are copy and paste from the past. No new patents over the last couple of years but is interesting all existing including tau have been published in all Countries i think? Tau the most recent and last in the US july 29, 2022.

<< Previous
Bullboard Posts
Next >>